Amirhosein Naseri, Mohammad Hossein Antikchi, Sepideh Soleymani, Mehdi Khosravi-Mashizi, Rezvan Nezameslami, Alireza Nezameslami, Bahareh Mehdikhani, Ahmad Shirinzadeh-Dastgiri, Seyed Masoud Haghighikian, Mohammad Vakili-Ojarood, Amirhossein Rahmani, Hossein Neamatzadeh
{"title":"PARP-1 rs1136410多态性与胃肠道癌症风险:癌症类型和种族特异性关联的荟萃分析","authors":"Amirhosein Naseri, Mohammad Hossein Antikchi, Sepideh Soleymani, Mehdi Khosravi-Mashizi, Rezvan Nezameslami, Alireza Nezameslami, Bahareh Mehdikhani, Ahmad Shirinzadeh-Dastgiri, Seyed Masoud Haghighikian, Mohammad Vakili-Ojarood, Amirhossein Rahmani, Hossein Neamatzadeh","doi":"10.4274/MMJ.galenos.2025.72708","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Poly (ADP-ribose) polymerase-1 (<i>PARP-1</i>) is a key enzyme in DNA repair pathways and has been implicated in cancer susceptibility. The rs1136410 polymorphism in the <i>PARP-1</i> gene has shown inconsistent associations with gastrointestinal cancer risk across populations. This meta-analysis aimed to evaluate the association between <i>PARP-1</i> rs1136410 polymorphism and the risk of colorectal cancer (CRC) and gastric cancer (GC), with a focus on ethnic differences.</p><p><strong>Methods: </strong>A systematic literature search was performed in PubMed, Scopus, EMBASE, Web of Science, Cochrane Library, BIOSIS, LILACS, CNKI, CBM, Wan Fang, and other regional databases up to February 1, 2025. Eligible case-control studies assessing the association between PARP- 1 rs1136410 polymorphism and CRC or GC were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under five genetic models using Comprehensive Meta-Analysis software.</p><p><strong>Results: </strong>Thirteen case-control studies were included, comprising 3.591 patients and 5.433 controls. For GC (8 studies; 1,784 cases and 2,521 controls), significant associations were observed under multiple genetic models: allele comparison (C vs. T: OR=2.01, 95% CI 1.04-3.91, p=0.039), homozygous comparison (CC vs. TT: OR=1.77, 95% CI 1.24-2.52, p=0.002), heterozygous comparison (CT vs. TT: OR=1.36, 95% CI 1.18-1.57, p<0.001), and recessive comparison (CC vs. CT+TT: OR=1.54, 95% CI 1.08-2.20, p=0.017). No significant association was detected for CRC (5 studies; 1.807 cases and 2.912 controls). Ethnic subgroup analysis revealed a protective effect against CRC in Caucasians but increased susceptibility in Asians.</p><p><strong>Conclusion: </strong>The <i>PARP-1</i> rs1136410 polymorphism is associated with elevated GC risk but not CRC, with ethnicity-dependent effects suggesting differential genetic susceptibility. These findings highlight the importance of considering population-specific genetic backgrounds in gastrointestinal cancer risk assessment, prevention, and precision medicine strategies.</p>","PeriodicalId":37427,"journal":{"name":"Medeniyet medical journal","volume":"40 3","pages":"116-127"},"PeriodicalIF":1.1000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12478637/pdf/","citationCount":"0","resultStr":"{\"title\":\"PARP-1 rs1136410 Polymorphism and Gastrointestinal Cancer Risk: A Meta-Analysis of Cancer-Type and Ethnic-Specific Associations.\",\"authors\":\"Amirhosein Naseri, Mohammad Hossein Antikchi, Sepideh Soleymani, Mehdi Khosravi-Mashizi, Rezvan Nezameslami, Alireza Nezameslami, Bahareh Mehdikhani, Ahmad Shirinzadeh-Dastgiri, Seyed Masoud Haghighikian, Mohammad Vakili-Ojarood, Amirhossein Rahmani, Hossein Neamatzadeh\",\"doi\":\"10.4274/MMJ.galenos.2025.72708\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Poly (ADP-ribose) polymerase-1 (<i>PARP-1</i>) is a key enzyme in DNA repair pathways and has been implicated in cancer susceptibility. The rs1136410 polymorphism in the <i>PARP-1</i> gene has shown inconsistent associations with gastrointestinal cancer risk across populations. This meta-analysis aimed to evaluate the association between <i>PARP-1</i> rs1136410 polymorphism and the risk of colorectal cancer (CRC) and gastric cancer (GC), with a focus on ethnic differences.</p><p><strong>Methods: </strong>A systematic literature search was performed in PubMed, Scopus, EMBASE, Web of Science, Cochrane Library, BIOSIS, LILACS, CNKI, CBM, Wan Fang, and other regional databases up to February 1, 2025. Eligible case-control studies assessing the association between PARP- 1 rs1136410 polymorphism and CRC or GC were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under five genetic models using Comprehensive Meta-Analysis software.</p><p><strong>Results: </strong>Thirteen case-control studies were included, comprising 3.591 patients and 5.433 controls. For GC (8 studies; 1,784 cases and 2,521 controls), significant associations were observed under multiple genetic models: allele comparison (C vs. T: OR=2.01, 95% CI 1.04-3.91, p=0.039), homozygous comparison (CC vs. TT: OR=1.77, 95% CI 1.24-2.52, p=0.002), heterozygous comparison (CT vs. TT: OR=1.36, 95% CI 1.18-1.57, p<0.001), and recessive comparison (CC vs. CT+TT: OR=1.54, 95% CI 1.08-2.20, p=0.017). No significant association was detected for CRC (5 studies; 1.807 cases and 2.912 controls). Ethnic subgroup analysis revealed a protective effect against CRC in Caucasians but increased susceptibility in Asians.</p><p><strong>Conclusion: </strong>The <i>PARP-1</i> rs1136410 polymorphism is associated with elevated GC risk but not CRC, with ethnicity-dependent effects suggesting differential genetic susceptibility. These findings highlight the importance of considering population-specific genetic backgrounds in gastrointestinal cancer risk assessment, prevention, and precision medicine strategies.</p>\",\"PeriodicalId\":37427,\"journal\":{\"name\":\"Medeniyet medical journal\",\"volume\":\"40 3\",\"pages\":\"116-127\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12478637/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medeniyet medical journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/MMJ.galenos.2025.72708\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medeniyet medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/MMJ.galenos.2025.72708","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
目的:聚(adp -核糖)聚合酶-1 (PARP-1)是DNA修复途径中的关键酶,与癌症易感性有关。PARP-1基因的rs1136410多态性与人群中胃肠道癌症风险的相关性不一致。本荟萃分析旨在评估PARP-1 rs1136410多态性与结直肠癌(CRC)和胃癌(GC)风险之间的关系,重点关注种族差异。方法:系统检索PubMed、Scopus、EMBASE、Web of Science、Cochrane Library、BIOSIS、LILACS、CNKI、CBM、万方等区域性数据库截至2025年2月1日的文献。纳入了评估PARP- 1 rs1136410多态性与CRC或GC之间关系的合格病例对照研究。采用综合meta分析软件计算5种遗传模型的合并优势比(ORs)和95%置信区间(ci)。结果:纳入13项病例对照研究,包括3.591例患者和5.433例对照。对于GC(8项研究,1784例病例和2521例对照),在多种遗传模型下观察到显著相关性:等位基因比较(C vs. T: OR=2.01, 95% CI 1.04-3.91, p=0.039),纯合子比较(CC vs. TT: OR=1.77, 95% CI 1.24-2.52, p=0.002),杂合子比较(CT vs. TT: OR=1.36, 95% CI 1.18-1.57, p)结论:PARP-1 rs1136410多态性与GC风险升高相关,但与CRC无关,种族依赖性效应提示差异遗传易感性。这些发现强调了在胃肠道癌症风险评估、预防和精准医疗策略中考虑人群特异性遗传背景的重要性。
PARP-1 rs1136410 Polymorphism and Gastrointestinal Cancer Risk: A Meta-Analysis of Cancer-Type and Ethnic-Specific Associations.
Objective: Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme in DNA repair pathways and has been implicated in cancer susceptibility. The rs1136410 polymorphism in the PARP-1 gene has shown inconsistent associations with gastrointestinal cancer risk across populations. This meta-analysis aimed to evaluate the association between PARP-1 rs1136410 polymorphism and the risk of colorectal cancer (CRC) and gastric cancer (GC), with a focus on ethnic differences.
Methods: A systematic literature search was performed in PubMed, Scopus, EMBASE, Web of Science, Cochrane Library, BIOSIS, LILACS, CNKI, CBM, Wan Fang, and other regional databases up to February 1, 2025. Eligible case-control studies assessing the association between PARP- 1 rs1136410 polymorphism and CRC or GC were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under five genetic models using Comprehensive Meta-Analysis software.
Results: Thirteen case-control studies were included, comprising 3.591 patients and 5.433 controls. For GC (8 studies; 1,784 cases and 2,521 controls), significant associations were observed under multiple genetic models: allele comparison (C vs. T: OR=2.01, 95% CI 1.04-3.91, p=0.039), homozygous comparison (CC vs. TT: OR=1.77, 95% CI 1.24-2.52, p=0.002), heterozygous comparison (CT vs. TT: OR=1.36, 95% CI 1.18-1.57, p<0.001), and recessive comparison (CC vs. CT+TT: OR=1.54, 95% CI 1.08-2.20, p=0.017). No significant association was detected for CRC (5 studies; 1.807 cases and 2.912 controls). Ethnic subgroup analysis revealed a protective effect against CRC in Caucasians but increased susceptibility in Asians.
Conclusion: The PARP-1 rs1136410 polymorphism is associated with elevated GC risk but not CRC, with ethnicity-dependent effects suggesting differential genetic susceptibility. These findings highlight the importance of considering population-specific genetic backgrounds in gastrointestinal cancer risk assessment, prevention, and precision medicine strategies.
期刊介绍:
The Medeniyet Medical Journal (Medeniyet Med J) is an open access, peer-reviewed, and scientific journal of Istanbul Medeniyet University Faculty of Medicine on various academic disciplines in medicine, which is published in English four times a year, in March, June, September, and December by a group of academics. Medeniyet Medical Journal is the continuation of Göztepe Medical Journal (ISSN: 1300-526X) which was started publishing in 1985. It changed the name as Medeniyet Medical Journal in 2015. Submission and publication are free of charge. No fees are asked from the authors for evaluation or publication process. All published articles are available online in the journal website (www.medeniyetmedicaljournal.org) without any fee. The journal publishes intradisciplinary or interdisciplinary clinical, experimental, and basic researches as well as original case reports, reviews, invited reviews, or letters to the editor, Being published since 1985, the Medeniyet Med J recognizes that the best science should lead to better lives based on the fact that the medicine should serve to the needs of society, and knowledge should transform society. The journal aims to address current issues at both national and international levels, start debates, and exert an influence on decision-makers all over the world by integrating science in everyday life. Medeniyet Med J is committed to serve the public and influence people’s lives in a positive way by making science widely accessible. Believing that the only goal is improving lives, and research has an impact on people’s lives, we select the best research papers in line with this goal.